HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells
Anticancer Research, 07/27/2012
Kim MJ et al. – Sorafenib is more effective in combination with histone deacetylase inhibitors (HDACIs) even for clear cell renal cell carcinomas (RCCs) harboring mutant von Hippel–Lindau (VHL).



